Scientists in Germany have made significant progress in developing a nasal vaccine that can effectively combat Covid-19. The vaccine works by introducing a weakened form of the coronavirus into the nose and throat, where it triggers an immune response without causing full-blown illness.
The researchers tested their vaccine on hamsters and found that two doses were able to block the virus from replicating in the animals' upper airways, achieving "sterilizing immunity" and preventing illness. This is a long-sought goal of the pandemic, as it would prevent the virus from taking hold in the body.
While this vaccine still has several hurdles to clear before it can be used on humans, other nasal vaccines are already being tested or have shown promising results in clinical trials. China and India have also rolled out nasal vaccines that use harmless adenoviruses to ferry their instructions into cells, but effectiveness data is still limited.
Experts say that caution is warranted, as the vaccine still needs to pass further testing before it can be widely used. However, they also note that the results are encouraging, and a pan-coronavirus vaccine that induces mucosal immunity and is long-lived could be a game-changer in the fight against Covid-19.
The German team's approach is based on a technique called codon pair deoptimization, which manipulates the genetic material of the virus to make it harder for cells to translate. This makes the vaccine more effective at targeting the full range of coronavirus targets, rather than just its spike proteins like current vaccines do.
Other nasal vaccines are also being developed, including one from Mount Sinai that can be produced cheaply in chicken eggs, and another using a live but weakened version of the virus. These studies are ongoing, and their results will provide crucial insight into the effectiveness of this approach.
Despite the promise of these new vaccines, there are still challenges to overcome, particularly with regards to respiratory infections being tough targets for inhaled vaccines. However, some experts argue that this is not a reason to give up on the approach entirely, as live attenuated viruses have already proven effective against other diseases like measles, mumps and rubella.
Ultimately, the success of these new nasal vaccines will depend on further testing and data from human trials. If they prove successful, it could provide a vital tool in the fight against Covid-19, particularly for vulnerable populations such as the elderly and immunocompromised individuals who are most at risk of severe illness.
The researchers tested their vaccine on hamsters and found that two doses were able to block the virus from replicating in the animals' upper airways, achieving "sterilizing immunity" and preventing illness. This is a long-sought goal of the pandemic, as it would prevent the virus from taking hold in the body.
While this vaccine still has several hurdles to clear before it can be used on humans, other nasal vaccines are already being tested or have shown promising results in clinical trials. China and India have also rolled out nasal vaccines that use harmless adenoviruses to ferry their instructions into cells, but effectiveness data is still limited.
Experts say that caution is warranted, as the vaccine still needs to pass further testing before it can be widely used. However, they also note that the results are encouraging, and a pan-coronavirus vaccine that induces mucosal immunity and is long-lived could be a game-changer in the fight against Covid-19.
The German team's approach is based on a technique called codon pair deoptimization, which manipulates the genetic material of the virus to make it harder for cells to translate. This makes the vaccine more effective at targeting the full range of coronavirus targets, rather than just its spike proteins like current vaccines do.
Other nasal vaccines are also being developed, including one from Mount Sinai that can be produced cheaply in chicken eggs, and another using a live but weakened version of the virus. These studies are ongoing, and their results will provide crucial insight into the effectiveness of this approach.
Despite the promise of these new vaccines, there are still challenges to overcome, particularly with regards to respiratory infections being tough targets for inhaled vaccines. However, some experts argue that this is not a reason to give up on the approach entirely, as live attenuated viruses have already proven effective against other diseases like measles, mumps and rubella.
Ultimately, the success of these new nasal vaccines will depend on further testing and data from human trials. If they prove successful, it could provide a vital tool in the fight against Covid-19, particularly for vulnerable populations such as the elderly and immunocompromised individuals who are most at risk of severe illness.